Inventor
GOSSELIN MICHAEL L
US15 patents
⚠️ This page may combine multiple inventors who share the name “GOSSELIN MICHAEL L”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BRISTOL MYERS SQUIBB CO
11 patentsUS9540424B2Jan 10, 2017
Serum albumin binding molecules
BRISTOL MYERS SQUIBB CO27 citations92
US10221438B2Mar 5, 2019
Serum albumin binding molecules
BRISTOL MYERS SQUIBB CO12 citations91
US10934572B2Mar 2, 2021
Serum albumin binding molecules
BRISTOL MYERS SQUIBB CO4 citations83
US10442851B2Oct 15, 2019
Serum albumin-binding fibronectin type III domains
BRISTOL MYERS SQUIBB CO5 citations83
US11203630B2Dec 21, 2021
Serum albumin-binding fibronectin type III domains
BRISTOL MYERS SQUIBB CO2 citations72
US11434275B2Sep 6, 2022
Fast-off rate serum albumin binding fibronectin type III domains
BRISTOL MYERS SQUIBB CO3 citations70
US10766946B2Sep 8, 2020
Fast-off rate serum albumin binding fibronectin type III domains
BRISTOL MYERS SQUIBB CO4 citations70
US11919954B2Mar 5, 2024
Anti-TREM-1 antibodies and uses thereof
BRISTOL MYERS SQUIBB CO1 citations69
US11155618B2Oct 26, 2021
Anti-TREM-1 antibodies and uses thereof
BRISTOL MYERS SQUIBB CO1 citations69
US12534511B2Jan 27, 2026
Serum albumin-binding fibronectin type III domains
BRISTOL MYERS SQUIBB CO0 citations62
US11952420B2Apr 9, 2024
Nucleic acids encoding anti-TREM-1 antibodies
BRISTOL MYERS SQUIBB CO0 citations59
T CELL SCIENCES INC
2 patentsUS5858969AJan 12, 1999
Therapeutic methods employing sialylated glycoforms of soluble complement receptor 1 (SCR 1)
T CELL SCIENCES INC72 citations94
US5456909AOct 10, 1995
Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
T CELL SCIENCES INC92 citations92